MMAP-12 CONVENTIONAL SURGICAL RESECTION VERSUS STEREOTACTIC RADIOSURGERY FOR 1-3 CM SINGLE BRAIN METASTASES

Abstract There is a paucity of studies comparing conventional surgical resection (CSR) and stereotactic radiosurgery (SRS) for single brain metastases (BMs). This study evaluates local treatment failure (LTF) in patients with single, treatment-naïve BMs measuring 1–3 cm in diameter, eligible for either SRS or CSR. We identified patients treated between 1998–2024 with either upfront single-fraction SRS or CSR with adjuvant or neoadjuvant radiation. Fine and Gray’s method was used to analyze predictors of LTF, and propensity score-matched analysis (PSMA) ensured cohort comparability between SRS and CSR by primary tumor type, systemic disease extent, and tumor volume. Among 645 patients (523 SRS; 122 CSR + radiation), CSR was associated with significantly lower 1- and 2-year cumulative LTF rates (4% and 8%) compared to SRS (19% and 23%; p=0.0001). Median tumor volume pre-matching was 7.45 cm³ for CSR and 1.80 cm³ for SRS (p<0.0001). On multivariate analysis, predictors of increased LTF included SRS (HR=5.1, 95% CI: 2.6–9.8; p<0.0001), melanoma (vs renal cell carcinoma, HR=2.2, 95% CI: 1.2-4.3; p=0.018), colorectal cancer (vs RCC, HR=3.4, 95% CI: 1.4-7.8; p=0.005), breast cancer (vs RCC, HR=2.4, 95% CI: 1.1-5.2; p=0.037), greater tumor volume (HR= 1.2, 95% CI: 1.0-1.4 per fold increase; p=0.032), and eloquent location (vs non-eloquent, HR=1.8, 95% CI: 1.1-2.8; p=0.014). In 84 matched pairs, CSR remained associated with lower 1- and 2-year LTF rates (5% and 9%) vs SRS (28% and 37%; HR=0.2; p<0.0001). Among patients with tumor volume ≤5.71 cm³ (2.2 cm diameter; n=69), SRS was significantly associated with local recurrence (HR= 13.5, 95% CI: 3.2-56.2; p=0.0004). In conclusion, for single BMs measuring 1–3 cm, CSR was associated with significantly lower LTF compared to SRS, particularly for lesions <2.2 cm or those from melanoma, breast, or colorectal primaries. These findings support the consideration of CSR to optimize local control.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2025-08-01
DOI
https://doi.org/10.1093/noajnl/vdaf123.051
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MMAP-12 CONVENTIONAL SURGICAL RESECTION VERSUS STEREOTACTIC RADIOSURGERY FOR 1-3 CM SINGLE BRAIN METASTASES

Dima Suki, Ian E. McCutcheon, Betty Y.S. Kim, Robert Y. North et al.
Neuro-Oncology Advances
Brain Metastases and Treatment
article

MMAP-12 CONVENTIONAL SURGICAL RESECTION VERSUS STEREOTACTIC RADIOSURGERY FOR 1-3 CM SINGLE BRAIN METASTASES

Dima Suki, Ian E. McCutcheon, Betty Y.S. Kim, Robert Y. North, Frederick F. Lang, Chibawanye Ene, Christina Abi Faraj, Jeffrey S. Weinberg, Sherise Desiree Ferguson, Sujit S. Prabhu, Heather Yan Lin, Franco DeMonte
article en

Abstract

Abstract There is a paucity of studies comparing conventional surgical resection (CSR) and stereotactic radiosurgery (SRS) for single brain metastases (BMs). This study evaluates local treatment failure (LTF) in patients with single, treatment-naïve BMs measuring 1–3 cm in diameter, eligible for either SRS or CSR. We identified patients treated between 1998–2024 with either upfront single-fraction SRS or CSR with adjuvant or neoadjuvant radiation. Fine and Gray’s method was used to analyze predictors of LTF, and propensity score-matched analysis (PSMA) ensured cohort comparability between SRS and CSR by primary tumor type, systemic disease extent, and tumor volume. Among 645 patients (523 SRS; 122 CSR + radiation), CSR was associated with significantly lower 1- and 2-year cumulative LTF rates (4% and 8%) compared to SRS (19% and 23%; p=0.0001). Median tumor volume pre-matching was 7.45 cm³ for CSR and 1.80 cm³ for SRS (p<0.0001). On multivariate analysis, predictors of increased LTF included SRS (HR=5.1, 95% CI: 2.6–9.8; p<0.0001), melanoma (vs renal cell carcinoma, HR=2.2, 95% CI: 1.2-4.3; p=0.018), colorectal cancer (vs RCC, HR=3.4, 95% CI: 1.4-7.8; p=0.005), breast cancer (vs RCC, HR=2.4, 95% CI: 1.1-5.2; p=0.037), greater tumor volume (HR= 1.2, 95% CI: 1.0-1.4 per fold increase; p=0.032), and eloquent location (vs non-eloquent, HR=1.8, 95% CI: 1.1-2.8; p=0.014). In 84 matched pairs, CSR remained associated with lower 1- and 2-year LTF rates (5% and 9%) vs SRS (28% and 37%; HR=0.2; p<0.0001). Among patients with tumor volume ≤5.71 cm³ (2.2 cm diameter; n=69), SRS was significantly associated with local recurrence (HR= 13.5, 95% CI: 3.2-56.2; p=0.0004). In conclusion, for single BMs measuring 1–3 cm, CSR was associated with significantly lower LTF compared to SRS, particularly for lesions <2.2 cm or those from melanoma, breast, or colorectal primaries. These findings support the consideration of CSR to optimize local control.

Neuro-Oncology AdvancesVol. 7(Supplement_2)
The University of Texas MD Anderson Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 69%
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.